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Introduction {#sec001}
============

*Mycobacterium tuberculosis* is the etiological factor of tuberculosis (TB), causes significant morbidity and mortality worldwide. In 2013, WHO reported 8.6 million people developed TB and 1.3 million died from the disease \[[@pone.0139414.ref001]\]. Increasing spreads of multidrug-resistant tuberculosis (MDR-TB) has worsened the situation and treatment of MDR-TB leads to the use of second line drugs. Emergence of extensively drug resistant tuberculosis (XDR-TB) indicates not only search for new diagnostic markers, drugs, amendment in second line treatment regimens but also to explore the unknown mechanisms of resistance in *M*. *tuberculosis* for developing novel drug targets. Aminoglycosides, AK and KM are important anti-mycobacterial drugs for category-II TB patients. Category II TB patients include those who had failed previous TB treatment, relapsed after treatment, or defaulted during previous treatment. Cumulative mechanisms associated with resistance to aminoglycosides include majorly mutation in ribosomal protein/16S rRNA \[[@pone.0139414.ref002]\], cell wall impermeability \[[@pone.0139414.ref003]\], enzymatic inactivation of drugs \[[@pone.0139414.ref004]\], trapping of drug \[[@pone.0139414.ref005]\], decreased inner membrane transport and active efflux pumps \[[@pone.0139414.ref006]\]. Two-third of *M*. *tuberculosis* isolates showed KM and AK resistance due to *rrs* mutation, however remaining 1/3^rd^ do not have these mutations suggesting the involvement of some other mechanism(s) for resistance. Developments in molecular and cellular biology have imposed doubts on the ability of genetic analysis alone to predict any complex phenotypes. As primarily proteins manifest most of the biological processes, information about the actual state of cell can be obtained by analyzing the protein patterns. 2-DE coupled with MALDI-TOF-MS and bioinformatic tools have now been accepted as major analytical tools for detection, identification and characterization of protein species \[[@pone.0139414.ref007]--[@pone.0139414.ref008]\]. Most of the published proteomic studies concentrate mainly on soluble proteins and there are few comprehensive reports \[[@pone.0139414.ref009]--[@pone.0139414.ref014]\] on membrane proteins. The identification and characterization of membrane or membrane associated proteins of *M*. *tuberculosis* is important due to their anticipated role in virulence and bacterial-host interactions. Membranes and membrane associated proteins are likely to function as enzymes, receptors, transporters or signal transducers that could be of vital importance to the microbe and hence could qualify as drug targets \[[@pone.0139414.ref015]--[@pone.0139414.ref018]\]. Comparative proteomic studies addressing whole cell proteins with second line aminoglycosides drug resistance isolates have been reported \[[@pone.0139414.ref008]\]. However, membrane and membrane associated proteome of aminoglycosides resistant *M*. *tuberculosis* isolates have not been addressed. To address this, we analyzed the membranes and membrane associated proteins of AM and KM resistant *M*. *tuberculosis* by proteomic and bioinformatic approach. Such information could be helpful for the development of newer diagnostics and therapeutic agents for better treatment particularly drug resistance TB.

Materials and Methods {#sec002}
=====================

*M*. *tuberculosis* isolates and drug susceptibility testing {#sec003}
------------------------------------------------------------

Five total suseptible (rifampicin, isoniazid, ethambutol, pyrazinamide, streptomycin, kanamycin and amikacin) and five AK & KM resistant (sensitive to first line drugs) *M*. *tuberculosis* isolates were obtained from Mycobacterial Repository Centre of National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra, India. Drug susceptibility testing (DST) for all the drugs were performed by LJ proportion \[[@pone.0139414.ref019]\] and REMA method \[[@pone.0139414.ref020]--[@pone.0139414.ref021]\]. REMA method uses the oxidation--reduction of colorimetric indicator resazurin for determination of drug resistance and minimal inhibitory concentration (MICs) of antimicrobial agents against *M*. *tuberculosis*. Resazurin, which is blue in its oxidized state, turns pink when reduced by viable cells.

Membrane and membrane associated protein fraction preparation {#sec004}
-------------------------------------------------------------

Mycobacterial cell lysate was prepared as described by \[[@pone.0139414.ref008] & [@pone.0139414.ref022]\] with slight modifications. Briefly, cells were suspended in sonication buffer with 1% v/v Triton X--100 and then broken by intermittent sonication at 4°C for 20 min. Homogenate was centrifuged at 12,000 g for 20 min at 4°C. Resulting supernatants were ultracentrifuged at 150,000 x *g* for 90 min. and the pellet (cell membrane) was collected, washed and dissolved in 2D rehydration buffer. Protein concentrations were estimated by Bradford method \[[@pone.0139414.ref023]\] using BSA as standard. Protein extractions were performed for three times in biological and technical replicas.

2DE, In gel digestion & MS {#sec005}
--------------------------

IEF & SDS-PAGE were carried out using the published protocol of "in gel rehydration" with slight modifications \[[@pone.0139414.ref008] & [@pone.0139414.ref024]\]. Gel images were analyzed using PDQuest Advanced software version 8.0.0 (BIORAD, Hercules, CA, USA). Protein spots which showed increased intensities with more than 1.5 fold were selected for identification. Equal amount of proteins were loaded in all gels and experiments were repeated in biological and technical replicates at least three times. In-gel digestion of proteins and MALDI-TOF/MS was carried out using published protocol \[[@pone.0139414.ref008] & [@pone.0139414.ref025]\]. Mass spectra of digested proteins were acquired using Autoflex II TOF/TOF 50 (Bruker Daltonik GmbH, Leipzig, Germany).

Validation by MS/MS analysis {#sec006}
----------------------------

Matched precursor peptide ions of identified proteins were selected for subsequent fragmentation using PSD for MS/ MS. Lift_ATT.lift method was open in flex control software; parent peak mass spectrum was acquired by hitting laser for 400--550 shots followed by acquisition of fragments of selected precursor ion for the same no. of shots. Both parent and fragment spectrums were pooled to generate MS/MS spectrum of a particular peptide. MS/MS spectrum was submitted to database using MASCOT wizard described in MS protocol \[[@pone.0139414.ref008]\]. The same parameters were used for MS/MS search in addition with fragment mass tolerance from 0.2 to 1.0 Da.

Bioinformatic analysis {#sec007}
----------------------

Protein sequences of selected proteins were retrieved from Tuberculist server <http://tuberculist.epfl.ch/> and their probable functions were predicted using published protocol of BLASTp, InterProScan, KEGG, docking and GPS-PUP \[[@pone.0139414.ref026]--[@pone.0139414.ref031]\].

Results {#sec008}
=======

The main aim of the study was to compare the membranes and membrane associated proteins profiles of AM and KM resistant (lacks *rrs* mutation) with total sensitive isolates. *rrs* gene encoding 16S rRNA, have been associated with amikacin and kanamycin resistance. Results of DST by REMA methods are represented in [Table 1](#pone.0139414.t001){ref-type="table"}. 2DE profile run in triplicates for all isolates was employed to compare the protein profiles and composite images are shown in [Fig 1](#pone.0139414.g001){ref-type="fig"}. Comparison of 2D gels by PDQuest Advanced software revealed seventeen protein spots (identified as twelve protein with its species) with consistently increased intensities in resistant as compared to sensitive isolates (cut limit ≥ 1.5 fold change in spot intensity). Student t-test was used for the statistical analysis by PDQuest Advanced software. The system picks up the spots with differential intensity of significant levels built in the system. To rule out the chance of any artifact, proteins showing equal intensity were considered as internal control (encircled in [Fig 1](#pone.0139414.g001){ref-type="fig"}). Protein spots encircled in [Fig 1](#pone.0139414.g001){ref-type="fig"} were taken as internal controls to monitor the equal loading on the gels. Magnified regions of these protein spots are shown in [Fig 2](#pone.0139414.g002){ref-type="fig"}. Proteins spots of increased intensities were identified by MALDI-TOF-MS ([Table 2](#pone.0139414.t002){ref-type="table"}) and their identity were further revalidated by MS/MS ([Table 3](#pone.0139414.t003){ref-type="table"}) taking at least three peptides to be matched. Detailed information of MS and MS/MS of all the proteins were shown in supporting files ([S1 Text](#pone.0139414.s001){ref-type="supplementary-material"} and [S2 Text](#pone.0139414.s002){ref-type="supplementary-material"}). The identified proteins were ATP synthase subunit alpha (Rv1308), Trigger factor (Rv2462c), Dihydrolipoyl dehydrogenase (Rv0462), Elongation factor Tu (Rv0685), Transcriptional regulator MoxR1(Rv1479), Universal stress protein (Rv2005c), 35kDa hypothetical protein (Rv2744c), Proteasome subunit alpha (Rv2109c), Putative short-chain type dehydrogenase/reductase (Rv0148), Bacterioferritin (Rv1876), Ferritin (Rv3841) and Alpha-crystallin/HspX (Rv2031c). Out of twelve, Rv1308, Rv0462, Rv2109c, Rv0148, Rv1876 and Rv3841 belonged to intermediary metabolism and respiration, Rv2005c and Rv2031c to virulence/detoxification/adaptation, Rv2462c to cell wall and cell processes, Rv2744c to conserved hypothetical, Rv1479 to regulatory proteins and Rv0685 to information pathways categories. The level of difference in protein spot intensity has been represented as densitometric ratio in [Table 2](#pone.0139414.t002){ref-type="table"}. These proteins were also reported in membrane fraction of *M*. *tuberculosis* complex by various authors \[[@pone.0139414.ref009]--[@pone.0139414.ref014]\].

![Composite images of 2DE profile *M*. *tuberculosis isolates* (a) Total susceptible (b) AM and KM resistant (Encircled spots are taken as internal control).](pone.0139414.g001){#pone.0139414.g001}

![Magnified regions of 2D gels showing proteins of increased intensity (a) Sensitive (b) Resistant.](pone.0139414.g002){#pone.0139414.g002}

10.1371/journal.pone.0139414.t001

###### Drug susceptibility profile of *M*. *tuberculosis* isolates included in this study.

![](pone.0139414.t001){#pone.0139414.t001g}

  S. No.   Isolates Code   Drug susceptibility profile by Proportion method   MIC by REMA method                                       
  -------- --------------- -------------------------------------------------- -------------------- --- --- --- ------- ------ -------- ------
  **1**    H~37~Rv         S                                                  S                    S   S   S   S       ≤0.2   ≤0.025   0.05
  **2**    S 1             S                                                  S                    S   S   S   S       2.0    0.1      0.1
  **3**    S 2             S                                                  S                    S   S   S   S       0.5    0.2      0.2
  **4**    S 3             S                                                  S                    S   S   S   S       ≤0.2   ≤0.025   0.05
  **5**    S 4             S                                                  S                    S   S   S   S       2.0    0.2      0.1
  **6**    S 5             **S**                                              S                    S   S   S   S       1.0    0.1      0.2
  **7**    R 1             **S**                                              S                    S   S   S   **R**   0.5    12       16
  **8**    R 2             **S**                                              S                    S   S   S   **R**   ≤0.2   16       32
  **9**    R 3             **S**                                              S                    S   S   S   **R**   1.0    16       16
  **10**   R 4             **S**                                              S                    S   S   S   **R**   1.0    32       12
  **11**   R 5             **S**                                              S                    S   S   S   **R**   ≤0.2   12       32

S: sensitive; R: resistant; Rifampicin (RIF), Isoniazid (INH), Ethambutol (EMB), Streptomycin (SM), Pyrazinamide (PZA), Amikacin (AK), Kanamycin (KM)

10.1371/journal.pone.0139414.t002

###### Details of proteins identified by Mass Spectrometry.

![](pone.0139414.t002){#pone.0139414.t002g}

  Spot No.   Accession Number        Protein identified                                  MASCOT Score   Nominal Mass (Da)   pI     Sequence Coverage %   ORF No.   Densitometric ratio of protein intensity between sensitive and resistant isolates   Functional category [\*](#t002fn001){ref-type="table-fn"}
  ---------- ----------------------- --------------------------------------------------- -------------- ------------------- ------ --------------------- --------- ----------------------------------------------------------------------------------- -----------------------------------------------------------
  **D1**     P63673 (ATPA_MYCTU)     ATP synthase subunit alpha                          172            59252               5.03   35%                   Rv1308    1: 1.54                                                                             1
  **D 2**    O53189 (TIG_MYCTU)      Trigger factor                                      55             50586               4.43   21%                   Rv2462c   1: 1.80                                                                             2
  **D 3**    P66004 (DLDH_MYCTU)     Dihydrolipoyl dehydrogenase                         125            49208               5.53   35%                   Rv0462    1: 1.62                                                                             1
  **D 4**    P66004 (DLDH_MYCTU)     Dihydrolipoyl dehydrogenase                         116            49208               5.53   35%                   Rv0462    1: 1.53                                                                             1
  **D 5**    P66004 (DLDH_MYCTU)     Dihydrolipoyl dehydrogenase                         52             49208               5.53   13%                   Rv0462    1: 1.60                                                                             1
  **D 6**    P0A558 (EFTU_MYCTU)     Elongation factor Tu                                193            43566               5.28   60%                   Rv0685    1: 1.58                                                                             3
  **D 7**    P0A558 (EFTU_MYCTU)     Elongation factor Tu                                143            43566               5.28   50%                   Rv0685    1: 1.73                                                                             3
  **D 8**    Q79FN7 (Q79FN7_MYCTU)   Transcriptional regulator MoxR1                     116            40738               5.96   32%                   Rv1479    1: 1.52                                                                             4
  **D 9**    P64921 (Y2005_MYCTU)    Universal stress protein                            61             30966               5.53   23%                   Rv2005c   1: 1.99                                                                             5
  **D 10**   P0C5C4 (35KD_MYCTU)     35kDa protein                                       124            29240               5.71   33%                   Rv2744c   1: 2.00                                                                             6,2
  **D11**    P0C5C4 (35KD_MYCTU)     35kDa protein                                       79             29240               5.71   61%                   Rv2744c   1: 1.69                                                                             6,2
  **D 12**   O33244 (PSA_MYCTU)      Proteasome subunit alpha                            69             26865               5.41   27%                   Rv2109c   1: 2.09                                                                             1
  **D 13**   P96825 (Y0148_MYCTU)    Putative short-chain type dehydrogenase/reductase   181            29760               5.26   59%                   Rv0148    1: 1.91                                                                             1
  **D14**    P63697 (BFR_MYCTU)      Bacterioferritin                                    54             18239               4.50   27%                   Rv1876    1: 2.70                                                                             1
  **D 15**   P96237 (BFRB_MYCTU)     Ferritin                                            114            20429               4.73   38%                   Rv3841    1: 1.83                                                                             1
  **D 16**   P0A5B7 (ACR_MYCTU)      Alpha-crystallin                                    148            16217               5.00   78%                   Rv2031c   1: 1.64                                                                             5
  **D 17**   P0A5B7 (ACR_MYCTU)      Alpha-crystallin                                    93             16217               5.00   54%                   Rv2031c   1: 1.98                                                                             5

\***Note:** 1- intermediary metabolism and respiration, 2- cell wall and cell processes, 3- information pathways, 4- regulatory proteins, 5- virulence, detoxification, adaptation, 6- conserved hypothetical's

10.1371/journal.pone.0139414.t003

###### MS/MS analysis of identified proteins.

![](pone.0139414.t003){#pone.0139414.t003g}

  Spot No.   Peak Mass (Da)   Protein Identified                                  Nominal Mass   Mascot Score   pI     Sequence of peptides             ORF No.
  ---------- ---------------- --------------------------------------------------- -------------- -------------- ------ -------------------------------- ---------
  **D1**     894.4477         ATP synthase subunit alpha                          59252          25             5.03   LDLSQYR                          Rv1308
             1264.7051        ATP synthase subunit alpha                          59252          18             5.03   VVNPLGQPIDGR                     Rv1308
             1289.6714        ATP synthase subunit alpha                          59252          21             5.03   ASEEEILTEIR                      Rv1308
             1297.7342        ATP synthase subunit alpha                          59252          19             5.03   QGVKEPLQTGIK                     Rv1308
             1313.7349        ATP synthase subunit alpha                          59252          60             5.03   HVLIIFDDLTK                      Rv1308
             1319.7631        ATP synthase subunit alpha                          59252          30             5.03   ALELQAPSVVHR                     Rv1308
             1553.7943        ATP synthase subunit alpha                          59252          48             5.03   EAYPGDVFYLHSR                    Rv1308
             1602.9144        ATP synthase subunit alpha                          59252          65             5.03   TGEVLSVPVGDGFLGR                 Rv1308
             1747.9579        ATP synthase subunit alpha                          59252          52             5.03   ASEEEILTEIRDSQK                  Rv1308
             1886.0888        ATP synthase subunit alpha                          59252          98             5.03   LSDDLGGGSLTGLPIIETK              Rv1308
             2612.4725        ATP synthase subunit alpha                          59252          51             5.03   GFAATGGGSVVPDEHVEALDEDKLAK       Rv1308
  **D2**     1291.7448        Trigger factor                                      50586          25             4.43   NQLPTMFADVR                      Rv2462c
             1378.8073        Trigger factor                                      50586          32             4.43   FNELLVEQGSSR                     Rv2462c
             1671.9877        Trigger factor                                      50586          81             4.43   EAMLDQIVNDALPSR                  Rv2462c
             1801.1078        Trigger factor                                      50586          94             4.43   LIAGLDDAVVGLSADESR               Rv2462c
             1903.1486        Trigger factor                                      50586          109            4.43   INVEVPFAELEPDFQR                 Rv2462c
             2158.3327        Trigger factor                                      50586          29             4.43   VRINVEVPFAELEPDFQR               Rv2462c
  **D3**     1621.8785        Dihydrolipoyl dehydrogenase                         49208          118            5.53   NYGVDVTIVEFLPR                   Rv0462
             1890.9713        Dihydrolipoyl dehydrogenase                         49208          63             5.53   VLQAIGFAPNVEGYGLDK               Rv0462
             1909.9795        Dihydrolipoyl dehydrogenase                         49208          48             5.53   SIIIAGAGAIGMEFGYVLK              Rv0462
             1980.9351        Dihydrolipoyl dehydrogenase                         49208          50             5.53   AFGISGEVTFDYGIAYDR               Rv0462
             2015.0726        Dihydrolipoyl dehydrogenase                         49208          13             5.53   THYDVVVLGAGPGGYVAAIR             Rv0462
             2276.1980        Dihydrolipoyl dehydrogenase                         49208          100            5.53   LVPGTSLSANVVTYEEQILSR            Rv0462
             2688.4487        Dihydrolipoyl dehydrogenase                         49208          25             5.53   LGVTILTATKVESIADGGSQVTVTVTK.D    Rv0462
             2774.4226        Dihydrolipoyl dehydrogenase                         49208          111            5.53   HGELLGGHLVGHDVAELLPELTLAQR       Rv0462
  **D4**     1161.6462        Dihydrolipoyl dehydrogenase                         49208          21             5.53   WDLTASELAR                       Rv0462
             1171.6699        Dihydrolipoyl dehydrogenase                         49208          39             5.53   NAELVHIFTK                       Rv0462
             1621.9626        Dihydrolipoyl dehydrogenase                         49208          51             5.53   NYGVDVTIVEFLPR                   Rv0462
             1891.1342        Dihydrolipoyl dehydrogenase                         49208          85             5.53   VLQAIGFAPNVEGYGLDK               Rv0462
             1981.1184        Dihydrolipoyl dehydrogenase                         49208          14             5.53   AFGISGEVTFDYGIAYDR               Rv0462
             2015.2435        Dihydrolipoyl dehydrogenase                         49208          15             5.53   THYDVVVLGAGPGGYVAAIR             Rv0462
  **D5**     895.5120         Dihydrolipoyl dehydrogenase                         49208          19             5.53   FPFTANAK                         Rv0462
             1161.7045        Dihydrolipoyl dehydrogenase                         49208          28             5.53   WDLTASELAR                       Rv0462
             1170.6847        Dihydrolipoyl dehydrogenase                         49208          20             5.53   AHGVGDPSGFVK                     Rv0462
             1171.7299        Dihydrolipoyl dehydrogenase                         49208          33             5.53   NAELVHIFTK                       Rv0462
             1397.9056        Dihydrolipoyl dehydrogenase                         49208          19             5.53   AAQLGLSTAIVEPK                   Rv0462
  **D6**     1404.5958        Elongation factor Tu                                43566          24             5.28   AFDQIDNAPEER                     Rv0685
             1413.7572        Elongation factor Tu                                43566          67             5.28   QVGVPYILVALNK                    Rv0685
             1555.7710        Elongation factor Tu                                43566          34             5.28   VLHDKFPDLNETK                    Rv0685
             1701.8430        Elongation factor Tu                                43566          28             5.28   GITINIAHVEYQTDK                  Rv0685
             1801.8729        Elongation factor Tu                                43566          76             5.28   .ELLAAQEFDEDAPVVR                Rv0685
             2074.9777        Elongation factor Tu                                43566          53             5.28   ADAVDDEELLELVEMEVR               Rv0685
             2195.1034        Elongation factor Tu                                43566          31             5.28   ETDKPFLMPVEDVFTITGR              Rv0685
             2356.1634        Elongation factor Tu                                43566          34             5.28   WVASVEELMNAVDESIPDPVR            Rv0685
  **D7**     1404.6006        Elongation factor Tu                                43566          28             5.28   AFDQIDNAPEER                     Rv0685
             1413.7786        Elongation factor Tu                                43566          70             5.28   QVGVPYILVALNK                    Rv0685
             1681.8413        Elongation factor Tu                                43566          110            5.28   LLDQGQAGDNVGLLLR                 Rv0685
             1801.8014        Elongation factor Tu                                43566          57             5.28   ELLAAQEFDEDAPVVR                 Rv0685
             2033.8394        Elongation factor Tu                                43566          15             5.28   HTPFFNNYRPQFYFR                  Rv0685
             2074.8391        Elongation factor Tu                                43566          48             5.28   ADAVDDEELLELVEMEVR               Rv0685
             2194.9570        Elongation factor Tu                                43566          52             5.28   ETDKPFLMPVEDVFTITGR              Rv0685
             2355.9810        Elongation factor Tu                                43566          40             5.28   WVASVEELMNAVDESIPDPVR            Rv0685
  **D8**     1785.8129        Transcriptional regulator MoxR1                     40738          27             5.96   IQFTPDLVPTDIIGTR                 Rv1479
             1982.8948        Transcriptional regulator MoxR1                     40738          29             5.96   DYVIPQDVIEVIPDVLR                Rv1479
             2196.0884        Transcriptional regulator MoxR1                     40738          43             5.96   GRDYVIPQDVIEVIPDVLR              Rv1479
             2244.1285        Transcriptional regulator MoxR1                     40738          94             5.96   LVLTYDALADEISPEIVINR             Rv1479
             2308.0928        Transcriptional regulator MoxR1                     40738          37             5.96   LQEIAANNFVHHALVDYVVR             Rv1479
             2491.0784        Transcriptional regulator MoxR1                     40738          21             5.96   EEFDTELGPVVANFLLADEINR           Rv1479
             2832.2880        Transcriptional regulator MoxR1                     40738          65             5.96   QGREEFDTELGPVVANFLLADEINR        Rv1479
  **D9**     859.4570         Universal stress protein                            30966          21             5.53   LAGWQER                          Rv2005c
             932.4974         Universal stress protein                            30966          56             5.53   YPDVPVSR                         Rv2005c
             1330.8178        Universal stress protein                            30966          11             5.53   GLLGSVSSSLVRR                    Rv2005c
             1367.8154        Universal stress protein                            30966          44             5.53   SASAQLVVVGSHGR                   Rv2005c
             1737.0408        Universal stress protein                            30966          53             5.53   LAGWQERYPDVPVSR                  Rv2005c
             1924.1982        Universal stress protein                            30966          44             5.53   GGLTGMLLGSVSNAVLHAAR             Rv2005c
  **D10**    1029.5576        35 kDa protein                                      29240          20             5.71   LLSQLEQAK                        Rv2744c
             1412.7607        35 kDa protein                                      29240          72             5.71   VQIQQAIEEAQR                     Rv2744c
             1424.7377        35 kDa protein                                      29240          13             5.71   TLHDQALSAAAQAK                   Rv2744c
             1525.8869        35 kDa protein                                      29240          56             5.71   QLADIEKLQVNVR                    Rv2744c
             1615.8335        35 kDa protein                                      29240          10             5.71   QALTLADQATAAGDAAK                Rv2744c
             1822.9247        35 kDa protein                                      29240          132            5.71   YANAIGSAELAESSVQGR               Rv2744c
             2783.3882        35 kDa protein                                      29240          84             5.71   ATEYNNAAEAFAAQLVTAEQSVEDLK       Rv2744c
  **D11**    1412.8493        35 kDa protein                                      29240          50             5.71   VQIQQAIEEAQR                     Rv2744c
             1525.9723        35 kDa protein                                      29240          49             5.71   QLADIEKLQVNVR                    Rv2744c
             1823.0114        35 kDa protein                                      29240          21             5.71   YANAIGSAELAESSVQGR               Rv2744c
             1864.0864        35 kDa protein                                      29240          136            5.71   THQALTQQAAQVIGNQR                Rv2744c
  **D12**    1054.5026        Proteasome subunit alpha                            26865          25             5.41   FNEFDNLR                         Rv2109c
             2020.1235        Proteasome subunit alpha                            26865          74             5.41   SVVALAYAGGVLFVAENPSR             Rv2109c
             2219.2512        Proteasome subunit alpha                            26865          24             5.41   AKSVVALAYAGGVLFVAENPSR           Rv2109c
             2924.3203        Proteasome subunit alpha                            26865          29             5.41   AGSADTSGGDQPTLGVASLEVAVLDANRPR   Rv2109c
  **D13**    884.4423         Putative short-chain type dehydrogenase/reductase   29760          13             5.26   AAWPHFR                          Rv0148
             1190.5693        Putative short-chain type dehydrogenase/reductase   29760          27             5.26   WAEITDLSGAK                      Rv0148
             1313.6913        Putative short-chain type dehydrogenase/reductase   29760          23             5.26   VHLYGGYHVLR                      Rv0148
             1339.6028        Putative short-chain type dehydrogenase/reductase   29760          53             5.26   MSFENWDAVLK                      Rv0148
             1581.9283        Putative short-chain type dehydrogenase/reductase   29760          90             5.26   LGLVGLINTLALEGAK                 Rv0148
             1748.8280        Putative short-chain type dehydrogenase/reductase   29760          14             5.26   DGTGAGSAMADEVVAEIR               Rv0148
             1921.9303        Putative short-chain type dehydrogenase/reductase   29760          36             5.26   AVANYDSVATEDGAANIIK              Rv0148
             2162.1125        Putative short-chain type dehydrogenase/reductase   29760          102            5.26   EYALTLAGEGASVVVNDLGGAR           Rv0148
             2388.1836        Putative short-chain type dehydrogenase/reductase   29760          58             5.26   VALFGNDGANFDKPPSVQDVAAR          Rv0148
  **D14**    1414.6818        Bacterioferritin                                    18239          79             4.50   ILLLDGLPNYQR                     Rv1876
             1776.6893        Bacterioferritin                                    18239          55             4.50   MQDNWGFTELAAHTR                  Rv1876
             1924.8015        Bacterioferritin                                    18239          45             4.50   EQFEADLAIEYDVLNR                 Rv1876
  **D15**    932.4086         Ferritin                                            20429          31             4.73   NQFDRPR                          Rv3841
             1084.5530        Ferritin                                            20429          54             4.73   VEIPGVDTVR                       Rv3841
             1228.6306        Ferritin                                            20429          27             4.73   EALALALDQER                      Rv3841
             1265.5885        Ferritin                                            20429          19             4.73   HFYSQAVEER                       Rv3841
             1550.8525        Ferritin                                            20429          105            4.73   AGANLFELENFVAR                   Rv3841
             1632.8621        Ferritin                                            20429          15             4.73   EVDVAPAASGAPHAAGGR               Rv3841
  **D16**    1095.5822        Alpha-crystallin                                    16217          36             5.00   TEQKDFDGR                        Rv2031c
             1162.6453        Alpha-crystallin                                    16217          66             5.00   SEFAYGSFVR                       Rv2031c
             1715.0573        Alpha-crystallin                                    16217          42             5.00   GILTVSVAVSEGKPTEK                Rv2031c
             1752.8950        Alpha-crystallin                                    16217          96             5.00   DFDGRSEFAYGSFVR                  Rv2031c
             1869.0448        Alpha-crystallin                                    16217          19             5.00   AELPGVDPDKDVDIMVR                Rv2031c
             2037.1053        Alpha-crystallin                                    16217          29             5.00   TVSLPVGADEDDIKATYDK              Rv2031c
             2950.6204        Alpha-crystallin                                    16217          13             5.00   SLFPEFSELFAAFPSFAGLRPTFDTR       Rv2031c
  **D17**    1162.4795        Alpha-crystallin                                    16217          65             5.00   SEFAYGSFVR                       Rv2031c
             1458.6522        Alpha-crystallin                                    16217          17             5.00   TVSLPVGADEDDIK                   Rv2031c
             1714.8305        Alpha-crystallin                                    16217          43             5.00   GILTVSVAVSEGKPTEK                Rv2031c
             1752.6882        Alpha-crystallin                                    16217          32             5.00   DFDGRSEFAYGSFVR                  Rv2031c
             1868.8202        Alpha-crystallin                                    16217          53             5.00   AELPGVDPDKDVDIMVR                Rv2031c
             2036.8814        Alpha-crystallin                                    16217          56             5.00   TVSLPVGADEDDIKATYDK              Rv2031c
             2293.0996        Alpha-crystallin                                    16217          17             5.00   ATYDKGILTVSVAVSEGKPTEK           Rv2031c

BLAST and InterProScan analysis {#sec009}
-------------------------------

BLASTP analysis was performed for proteins of unknown function. Rv0148 was found to be highly conserved in mycobacterial and bacterial species as putative short chain dehydrogenase/reductase protein. InterProScan analysis of Rv0148 showed motifs (PF00106) from residues 8--183 which provides a signature for short chain dehydrogenase. Rv2005c was found to be highly conserved in mycobacterial and bacterial species as universal stress protein, in some mycobacterial species it appeared as hypothetical protein with unknown function. InterProScan analysis of Rv2005c showed the presence of two signature motifs of Usp domain with amino acid residues from10-148 and 162--293 (PF00582) and three signatures motifs of universal stress protein with amino acid residues from 159--177, 253--265 and 271--293 (PRINTS: PR01438). Rv2744c was found to be conserved alanine rich hypothetical protein, exhibited significant homology with hypothetical and phase shock protein A (pspA) of all *M*. *tuberculosis complex* and NTMs. InterProScan analysis of Rv2744c showed the presence of PspA domain with amino acid residues from 3--242 (PF04012).

Multiple Sequence Alignment {#sec010}
---------------------------

Multiple sequence alignment of mtu (*M*. *tuberculosis*) proteins was performed for the set of five organism's mbo (*M*. *bovis*), maf (*M*. *africanum*), mav (*M*. *avium*), mle (*M*. *leprae*) and hsa (*Homo sapiens*) {[Table 4](#pone.0139414.t004){ref-type="table"}}. Results showed that hypothetical proteins (Rv0148, Rv2005c and Rv2744c) exhibited 100% homology (except Rv2744c- 99.60% and 99.30% homology) to their corresponding proteins in *M*. *bovis* and *M*. *africanum* which are members of tuberculosis complex. In *M*. *avium*, \> 87% homology has been seen, except Rv2005c (64.40%). Less than 48% of homology has been seen with *M*. *leprae* and *Homo sapiens* to their corresponding proteins as well as with other proteins.

10.1371/journal.pone.0139414.t004

###### Multiple sequence alignment of the hypothetical proteins with defined set of organisms.

![](pone.0139414.t004){#pone.0139414.t004g}

  ORF Number    Mbo (*M*. *bovis*)   Maf (*M*. *africanum*)   Mav (*M*. *avium*)   Mle (*M*. *leprae*)   Has (*Homo*. *sapiens*)
  ------------- -------------------- ------------------------ -------------------- --------------------- -------------------------
  **Rv0148**    100%                 100%                     87.30%               23.42%                47.50%
  **Rv2005c**   100%                 100%                     64.40%               28.10%                21.70%
  **Rv2744c**   99.6%                99.30%                   88.00%               26.60%                24.60%

3D modeling and docking {#sec011}
-----------------------

Molecular docking analysis of selected 3D models (showing less than 2% discrepancy from Ramachandran plot) of hypothetical proteins was performed to detect their binding with AK and KM. Parameters used for selection of 3D models and molecular docking are represented in [Table 5](#pone.0139414.t005){ref-type="table"}. Docking of Rv0148 and Rv2005c ([Fig 3](#pone.0139414.g003){ref-type="fig"}) showed the interaction of both drugs into the central cavity of conserved motif of SDR domain and Usp domain of hypothetical proteins respectively. Interacting residues were almost common for both drugs, which suggests similar binding site for both. Docking with Rv2744c show that both drugs interact at the similar interacting residue of conserved PspA domain of hypothetical protein. With Rv3841 both drugs interacted with amino acids of conserved ferritin domain as well as domain of unknown function.

![3D model of hypothetical proteins & ferritin showing docking with AK & KM: A1 and A2 shows molecular docking of Rv0148 with AM (red) & KM (blue) respectively, orange color shows SDR domain, yellow color shows interacting residues of SDR domain.\
B1 and B2 shows molecular docking of Rv2005c with AM (red) & KM (blue) respectively, orange color shows Usp domain, yellow color shows interacting residues of Usp domain. C1 and C2 shows docking of Rv2744c with AM (red) & KM (blue) respectively, orange color shows PspA domain of hypothetical protein, yellow color shows interacting residues of PspA domain. D1 and D2 shows docking of Rv3841 with AM (red) & KM (blue) respectively, orange color shows conserved ferritin domain of protein, yellow color shows interacting residues of conserved ferritin domain, purple color shows interacting residues of unknown domain.](pone.0139414.g003){#pone.0139414.g003}

10.1371/journal.pone.0139414.t005

###### 3D modeling and docking parameters used for bioinformatic analysis.

![](pone.0139414.t005){#pone.0139414.t005g}

  ORF No.       TM-score    RMSD value (Å)   Drug   Global Energy   Attractive Vander wall forces   Repulsive Vander wall forces   ACE      Interacting amino acids                                            Remarks
  ------------- ----------- ---------------- ------ --------------- ------------------------------- ------------------------------ -------- ------------------------------------------------------------------ -------------------------------------------------------------------------------------------
  **Rv0148**    0.81±0.09   4.6±3.0Å         AK     -29.30          -20.55                          19.86                          -10.46   18,99,123,149,150,152,153,158,161,164,168,194--196,198,200 & 201   AK binds properly within the central cavity of conserved SDR domain
  **Rv0148**    0.81±0.09   4.6±3.0Å         KM     -45.45          -22.03                          10.90                          -14.08   99,103,123,149,150--152,164,168,194--196,198,200 & 201             KM also binds within the central cavity of conserved SDR domain
  **Rv2005c**   0.95±0.05   2.8±2.0Å         AK     -32.66          -20.26                          8.27                           -06.23   15,16,42,43,64,67,71,100,101,120,121 & 130--132                    AK binds in central cavity of conserved motif of Usp domain
  **Rv2005c**   0.95±0.05   2.8±2.0Å         KM     -31.64          -18.15                          3.76                           -05.29   14,15,16,42,43,44,64,67,71,100,120,121 & 122                       KM also binds in central cavity of conserved motif of Usp domain of hypothetical protein
  **Rv2744c**   0.30±0.10   15.3±3.4Å        AK     -22.56          -22.44                          7.00                           00.59    19,20,22,25,29,36,38,39,40,41 & 44                                 AK interact to conserved motif of PspA domain
  **Rv2744c**   0.30±0.10   15.3±3.4Å        KM     -25.82          -16.56                          2.90                           -03.51   19,20,22,25,29,36,38,39,40,41,44 & 230                             KM also interact to conserved motif of PspA domain of hypothetical protein
  **Rv3841**    0.92±0.06   2.3±1.7Å         AK     -26.34          -16.62                          4.97                           -7.23    134,137,138,141,144,163, 164,165,166,167,168,169& 170              AK binds to close vicinity of conserved ferritin domain & domain of unknown function
  **Rv3841**    0.92±0.06   2.3±1.7Å         KM     -34.66          -19.57                          7.05                           -9.35    134,135,137,138,141,144,163,164,165,166,167,168,169 &170           KM also binds to close vicinity of conserved ferritin domain & domain of unknown function

Prediction of pupylation sites {#sec012}
------------------------------

By utilizing the default threshold (medium), GPS-PUP predicted six pupylation sites at position K7, K71, K94, K120, K134, and K135 in Rv2744c. Rv2005c and Rv0148 showed two pupylation sites at position K80, K248 and K280, K285 respectively ([Table 6](#pone.0139414.t006){ref-type="table"}).

10.1371/journal.pone.0139414.t006

###### Predicted / identified pupylation sites within identified proteins.

![](pone.0139414.t006){#pone.0139414.t006g}

  ORF No.   Position of lysine residue undergoes pupylation   Peptide                     Score   Cut-off
  --------- ------------------------------------------------- --------------------------- ------- ---------
  Rv2005c   80                                                ANAVKLA**K**EAVGADR         3.488   2.452
            248                                               VCDRPAR**K**LVQKSAS         3.858   2.452
  Rv0148    280                                               ITDLSGA**K**IAGFKL\*        3.11    2.452
            285                                               GAKIAGF**K**L\*\*\*\*\*\*   2.748   2.452
  Rv2744c   7                                                 \*MANPFV**K**AWKYLMA        3.15    2.452
            71                                                RQLADIE**K**LQVNVRQ         3.315   2.452
            94                                                TAAGDAA**K**ATEYNNA         2.787   2.452
            120                                               EQSVEDL**K**TLHDQAL         3.063   2.452
            134                                               LSAAAQA**K**KAVERNA         2.835   2.452
            135                                               SAAAQAK**K**AVERNAM         2.496   2.452

Discussion {#sec013}
==========

In this study we used a proteomic approach to compare membrane and membrane associated proteins of AK and KM resistant and susceptible isolates by 2DE, MALDI-TOF/MS and bioinformatic tools. Resistant isolates were also sequenced and analyzed for known rrs mutations. These isolates did not exhibit mutations at the reported sites. Proteins with increased intensities in the resistant isolates were identified, which might be used as diagnostic markers or drug targets for therapeutics. 2DE/MS has an advantage over the traditional methods (SDS-PAGE, chromatography and sequencing) as not only the identification of a large number of unknown proteins but also protein species separation. Several reports for identification of diagnostics and drug targets employing proteomic approaches exist \[[@pone.0139414.ref032]--[@pone.0139414.ref033]\]. However, to the best of our knowledge, no such membrane proteome analysis with AK & KM resistant *M*. *tuberculosis* isolates has been reported.

Our study revealed twelve proteins with increased intensity in AM and KM resistant as compared to total susceptible isolates. Five spots matched with already identified protein species and therefore total seventeen protein spots were found to be upregulated. Out of twelve, Rv1308, Rv0462, Rv2109c, Rv0148, Rv1876 and Rv3841 belonged to intermediary metabolism and respiration, Rv2005c and Rv2031c to virulence/detoxification/adaptation, Rv2462c to cell wall and cell processes, Rv2744c to conserved hypothetical, Rv1479 to regulatory proteins and Rv0685 to information pathways categories. These proteins were membrane associated \[[@pone.0139414.ref009]--[@pone.0139414.ref014]\] but were not purely membrane proteins having transmembrane helix. This might be due to the selection of consistently increased intensities of spots in resistant as compared to sensitive isolates (cut limit ≥ 1.5 fold changes in spot intensity).This suggests that membranes with trans membrane helix do not show consistently increased intensities up to 1.5 fold.

Rv1308 (ATP synthase subunit alpha) is a regulatory subunit that produces ATP in the presence of proton gradient across the membrane. Mycobacteria reside in specialized niches and may require adaptations in the energy metabolism. It has been reported that it not only stipulates in replicating mycobacteria, but also in the dormant state \[[@pone.0139414.ref034]--[@pone.0139414.ref036]\]. Rv0462 (Dihydrolipoyl dehydrogenase/Lpd) is involved in energy metabolism and antioxidant defense. It is the third enzyme of *M*. *tuberculosis*'s pyruvate dehydrogenase complex and first enzyme of peroxynitrite reductase/peroxidase, which helps *M*. *tuberculosis* to resist host reactive nitrogen intermediates. Without Lpd, *M*. *tuberculosis* cannot metabolize branched-chain amino acids and potentially toxic branched-chain intermediates accumulate \[[@pone.0139414.ref037]\]. Heo et al \[[@pone.0139414.ref038]\] reported that this protein induces dendritic cells maturation, Th1-mediated responses and may contribute to vaccine development against *M*. *tuberculosis* infection. Rv2109c (Proteasome subunit alpha) is involved in protein degradation and required for the virulence of *M*. *tuberculosis*. It not only degrades proteins that are toxic due to oxidative or nitrosative damage but also allows other proteins to participate in NO detoxification or repair of macromolecules \[[@pone.0139414.ref039]\]. Fortune et al \[[@pone.0139414.ref040]\] reported its involvement in regulating the synthesis of secreted or surface proteins that alter host immunity and thus favor persistence. Discovery of pupylome in *M*. *tuberculosis* \[[@pone.0139414.ref041]\] and other conserved proteasomal components like proteasome b/a subunits, recognition ATPase, pupylase, and depupylome revealed the protein regulation and turnover through proteasome. Identity of these proteins began to explain why defects in protein degradation attenuate virulence *in vivo* \[[@pone.0139414.ref042]--[@pone.0139414.ref043]\]. Rv0148 has been identified as probable short-chain dehydrogenases/reductases and possess two binding domains- NAD and substrate. *M*. *tuberculosis* acquires Rv0148 gene via horizontal gene transfer from eukaryotics. As the gene has been retained in the genome through selective advantage, it might play a key role in pathogenesis and immunomodulation \[[@pone.0139414.ref044]\].

Rv1876 (bacterioferritin) and Rv3841 (ferritin), unique for iron homeostasis and are increased intensities under iron-rich and decreased under iron deprived conditions \[[@pone.0139414.ref045]\]. Very little is known about the protein-protein interactions that carry iron for storage or promote the mobilization of stored iron from ferritin like molecules. Iron assimilation and utilization in *M*. *tuberculosis* plays a crucial role in growth, virulence and latency. Function of these may not be just limited to iron uptake; they may be contributing to other metabolic activities, the mechanism of which is still unclear. Pandey and Rodriguez \[[@pone.0139414.ref046]\] suggested that ferritin (bfrB) is mandatory to maintain iron homeostasis in *M*. *tuberculosis* and ferritin lacking bacilli are more susceptible to killing by antibiotics. Our results showed increased intensities of both ferritin and bacterioferritin in membrane fraction. Earlier we reported that only bacterioferritin intensity increased in whole cell lysate and suggested its role in imparting resistance to AK and KM \[[@pone.0139414.ref008]\]. It is assumed that the heme group present might seize its site of action by providing abnormal site for binding or modulating the protein to block its binding site which needs to be further explored. Although the pathways and enzymes involved in iron metabolism in *M*. *tuberculosis* are well established, still our information on iron dependent post-transcriptional, translational regulations, outer membrane iron transporters, trafficking and partitioning of siderophores/Fe-loaded apoproteins in mycobacteria is inadequate. Consequently, it can be a promising antimycobacterial target.

Rv2031c (Alpha-crystallin/HspX), a heat shock protein and Rv2005c (universal stress protein) are not only involved in cell protection to diverse stimuli like stress, dormancy, heat, drug and hypoxia by preventing protein aggregation but have established roles in resistance/stress/virulence/dormancy \[[@pone.0139414.ref047]\]. Rv2031c is regulated by the two-component regulatory system (DosR/DevR regulon) and is a latency stage disease marker \[[@pone.0139414.ref048]--[@pone.0139414.ref049]\]. Heat shock proteins assist in *M*. *tuberculosis* survival and also provide signal to the immune response \[[@pone.0139414.ref050]\]. Rv2031c and Rv2005c were predicted as a strong vaccine candidate by Zvi A et al \[[@pone.0139414.ref051]\].

Rv2462c (trigger factor), involved in protein export, acts as chaperone by maintaining the newly synthesized protein in an open conformation. It was reported to have increased intensity during nutrient deprivation in *M*. *tuberculosis* \[[@pone.0139414.ref052]\]. Rifat et al \[[@pone.0139414.ref053]\] reported that its intensity is regulated by inorganic phosphate limitation and suggested to play an important role in the survival of *M*. *tuberculosis* during chronic infection.

Rv2744c (35-kDa antigen), a hypothetical protein, is homologous to phage shock protein A (PspA) of *E*. *coli* and a predominant binding partner and substrate of PepD for proteolysis \[[@pone.0139414.ref054]\]. It was found to exhibit increased intensity upon exposure to vancomycin and cell wall damaging antibiotics suggesting their role in resistance to cell envelope stress \[[@pone.0139414.ref055]\]. PepD proteolytically regulates Rv2744c levels to maintain cell wall/cell envelope homeostasis in *M*. *tuberculosis*. It is also speculated that cleavage of Rv2744c by PepD may represent a mechanism for terminating the membrane stress response following cessation of the inducing stimulus. Future studies are aimed at delineating the specific mechanism by which it participates in cell wall homeostasis, and defining the other factors that participate in this stress response pathway.

Rv1479 (MoxR1) is a probable transcriptional regulator involved in regulatory function. Jungblut et al \[[@pone.0139414.ref056]\] found that four MoxR protein species were with different mobility. Hu et al \[[@pone.0139414.ref057]\] reported that MoxR1 m-RNA expression was more than four-fold in persisters compared to stationary phase of mycobacteria. Recently Rv1479 has been reported in *M*. *tuberculosis* pellicles \[[@pone.0139414.ref058]\]. Our study assumes that increased intensity of this protein overcomes the burden of the transcriptional regulation.

Rv0685 (Elongation factor--Tu) is a conserved protein involved in the elongation phase of translation and post-translational modifications. It also has RNA chaperone activities, ensuring that tmRNA adopts an optimal conformation during aminoacylation \[[@pone.0139414.ref059]\]. Ef-Tu phosphorylation is implicated in acclimation to the stress conditions encountered during the course of infection. *M*. *tuberculosis* phosphoproteome revealed Ef-Tu to be phosphorylated, Sajid et al \[[@pone.0139414.ref060]\] reported that phosphorylation of Ef-Tu by Protein Kinase B reduced its interaction with GTP, suggesting reduction in protein synthesis. In our study intensity of Rv0685 might be increased due to interruption of translational steps (primary target sites of aminoglycosides) and accumulation of Rv0685 might occur.

In the present study we observed that on performing docking analysis, both drugs interacted with conserved residues of Usp, SDR, PspA and ferritin domain of Rv2005c, Rv0148, Rv2744c and Rv3841 respectively which might alter their functions. It is predicted that these proteins might be exhibiting increased intensities to compensate the effect of drugs. Further we also found pupylation sites in Rv0148, Rv2005c and Rv2744c. Pupylation is a PTM through which small disordered protein Pup is conjugated to lysine residues of proteins marking them for proteasomal degradation. As modification with pup is reversible, pupylation is also likely to have a regulatory role \[[@pone.0139414.ref042]\]. Pup-proteasome system controlled by pupylation contributes to the virulence/survival strategy of *M*. *tuberculosis* in the host and makes the bacteria more resistant to various stresses \[[@pone.0139414.ref061]\]. Therefore it is assumed that pupylation of modulated protein (drug-protein complex) might be undergo turnover by proteasome machinery to overcome stress through protein-protein interaction. We assume that increased intensities of proteins might be contributing in imparting resistance against AK and KM. Further, detailed study in this direction may help in searching for new targets for drug development.

Conclusion {#sec014}
==========

In a nutshell, this is the first report on the membrane and membrane associated proteins of AK and KM resistance in *M*. *tuberculosis* using proteomic coupled with bioinformatic approaches. Among the twelve proteins which were found to have increased intensities only nine were with defined roles and three with unknown functions. Molecular docking showed proper interaction of both drugs with hypothetical proteins (Rv2005c, Rv2744c and Rv0148) as well as ferritin. GPS-PUP analysis suggested presence of pupylation sites within these proteins. It is depicted that increased intensities of these proteins and proteasome sub unit alpha might not only be neutralizing/modulating the drug molecules but are also involved in protein turnover to overcome AK and KM resistance. Apart from that we found three proteins--ferritin, bacterioferritin and elongation factor-Tu, involved in iron storage, homeostasis, detoxification, and regulation/metabolism. We assume that iron regulation/metabolism might be playing some crucial role in contributing resistance to AK and KM. Increased elongation factor-Tu (Rv0685) might be due to interruption of translational steps by these drugs. These findings need further exploitation for the development of newer therapeutic agents or molecular markers which can directly be targeted to a gene/protein responsible for resistance so that an extreme condition like XDR-TB can be prevented, which could ultimately lead to broaden the narrow gauge of new or existing therapeutics.
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